ANTH:OTC-Anthera Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 0.03

Change

0.00 (0.00)%

Market Cap

USD 0.65M

Volume

0.03M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

N/A

USD164.65B 24.98 2.76
CMXHF CSL Limited

N/A

USD97.05B 42.41 25.71
CSLLY CSL Limited

N/A

USD95.30B 43.19 25.71
GNMSF Genmab A/S

N/A

USD23.27B 25.66 2.93
UCBJF UCB SA

N/A

USD22.12B 24.73 18.77
UCBJY UCB SA

N/A

USD21.81B 24.83 18.77
SBHMY Sino Biopharmaceutical Limited

N/A

USD21.38B 56.11 3.56
SBMFF Sino Biopharmaceutical Limited

N/A

USD20.54B 59.30 3.56
PPTDF PeptiDream Inc

N/A

USD5.14B 260.99 1.35
MPSYF MorphoSys AG

N/A

USD4.05B 32.27 28.84

ETFs Containing ANTH

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.33% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.33% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -45.00% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -45.00% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -99.95% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.95% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -72.16% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -72.16% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 24.35% N/A N/A N/A N/A
Risk Adjusted Return -296.35% N/A N/A N/A N/A
Market Capitalization 0.65M N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.11 N/A N/A N/A N/A
Price / Cash Flow Ratio -0.02 N/A N/A N/A N/A
EV/EBITDA 0.21 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -568.85% N/A N/A N/A N/A
Return on Invested Capital -1,044.65% N/A N/A N/A N/A
Return on Assets -141.96% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.09 N/A N/A N/A N/A
Short Percent 10.45% N/A N/A N/A N/A
Beta 2.25 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.